Balanced news tone
News Sentiment
RHY sentiment intelligence
Rhythm Biosciences Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
21 relevant articles
Price is moving more forcefully than the current news tone suggests.
90/100 classification confidence.
directly relevant articles
high-authority source matches
-5.2% over one week, -17.3% over four weeks, trend inactive, and below fair value.
Rhythm Biosciences (ASX:RHY) Shares Climb 14%: Here's What Investors Are Watching
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
90/100 classification
One-week reaction
-5.2%
Price reacting lower
Trend fit
Trend inactive
-17.3% over four weeks
Fair value
-28.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
19
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kalkine
Direct company coverage
Rhythm Biosciences (ASX:RHY) Shares Climb 14%: Here's What Investors Are Watching
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Rhythm Biosciences (ASX:RHY): Why This ASX Biotech Stock Down Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Kalkine
Stocks Down Under
Direct company coverage
Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Stocks Down Under
Kalkine
Direct company coverage
Rhythm Biosciences (ASX:RHY) Shares Jump as Investors Track Healthcare Sector Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- Kalkine
Stocks Down Under
Direct company coverage
Rhythm Biosciences (ASX:RHY) is now cleared to offer its ColoSTAT test to patients in Australia!
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Mar 2026 01:24
- Source
- Stocks Down Under
The Australian
Direct company coverage
Rhythm inks local distribution deal for its next-gen bowel cancer assay
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Feb 2026 08:00
- Source
- The Australian
Stocks Down Under
Direct company coverage
Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- Stocks Down Under
Stocks Down Under
Direct company coverage
A Blood Test Instead of a Colonoscopy? Rhythm Biosciences (ASX:RHY) Takes Its First Commercial Step
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Feb 2026 08:00
- Source
- Stocks Down Under
smallcaps.com.au
Direct company coverage
Rhythm Biosciences begins ColoSTAT commercial deployment with first physician enrollment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Feb 2026 08:00
- Source
- smallcaps.com.au
simplywall.st
Direct company coverage
The 38% return this week takes Rhythm Biosciences' (ASX:RHY) shareholders one-year gains to 167%
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Feb 2026 08:00
- Source
- simplywall.st
smallcaps.com.au
Direct company coverage
Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Feb 2026 08:00
- Source
- smallcaps.com.au
The Australian
Direct company coverage
Rhythm’s ColoSTAT blood test clinically validated
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- The Australian
The Australian
Direct company coverage
Long Shortz: Rhythm Biosciences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Dec 2025 08:00
- Source
- The Australian
The Australian
Direct company coverage
Rhythm launches ColoSTAT in Australia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2025 08:00
- Source
- The Australian
Stocks Down Under
Direct company coverage
Is Rhythm Biosciences (ASX:RHY) a Buy After Securing NHS Expertise and US Distribution Deal?
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 11 Dec 2025 08:00
- Source
- Stocks Down Under
Stocks Down Under
Direct company coverage
Rhythm Biosciences (ASX: RHY): Interview with CEO David Atkins
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Oct 2024 07:00
- Source
- Stocks Down Under
intelligentinvestor.com.au
Direct company coverage
Rhythm Biosciences Limited (ASX: RHY) - Share Price
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Feb 2020 22:23
- Source
- intelligentinvestor.com.au
intelligentinvestor.com.au
Direct company coverage
Rhythm Biosciences Limited (ASX: RHY) - Announcements
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Oct 2019 04:07
- Source
- intelligentinvestor.com.au
intelligentinvestor.com.au
Direct company coverage
Rhythm Biosciences Limited (ASX:RHY)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Sep 2019 18:52
- Source
- intelligentinvestor.com.au
TradingView
Direct company coverage
RHY Stock Price and Chart — ASX:RHY
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Dec 2017 06:08
- Source
- TradingView
AFR
Direct company coverage
Rhythm Biosciences aims for ASX listing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Dec 2017 08:00
- Source
- AFR